Otsuka Pharmaceutical acquired Astex Pharmaceuticals for approximately $886 million via an all-cash tender offer at $8.50 per share (a roughly 48% premium), gaining the Dacogen/decitabine franchise and Astex's PYRAMID fragment-based drug discovery platform.